Mylan Inc. has launched escitalopram tablets, which the company said is the first equivalent product to Forest Laboratories' Lexapro antidepressant.


Mylan, escitalopram tablets, Lexapro, generic medication, antidepressant, Mylan Pharmaceuticals, Forest Laboratories, Heather Bresch, major depressive disorder, MDD, generalized anxiety disorder, GAD


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan introduces generic version of Lexapro

February 29th, 2012

PITTSBURGH – Mylan Inc. has launched escitalopram tablets, which the company said is the first equivalent product to Forest Laboratories' Lexapro antidepressant.

Mylan said Wednesday that its escitalopram product, released by its Mylan Pharmaceuticals Inc. subsidiary, comes in strengths of 5 mg, 10 mg and 20 mg.

Plans call for Mylan to market the generic medication exclusively until the expiration of the pediatric exclusivity on the compound patent, as per the settlement agreement between its Alphapharm subsidiary and Forest Labs.

"We are extremely pleased to be the first company to offer the first equivalent product to Lexapro, allowing customers, payers and patients to realize significant savings from our high-quality, more affordable treatment option," Mylan chief executive officer Heather Bresch said in a statement. 

Escitalopram is used for acute and maintenance treatment of major depressive disorder (MDD) and acute treatment of generalized anxiety disorder (GAD). 

According to Mylan, Lexapro had U.S. sales of about $2.9 billion for the 12 months ended Dec. 31, 2011, based on IMS Health data.

Advertisement